Skip to main content
. 2017 Aug 31;8(8):e3029. doi: 10.1038/cddis.2017.406

Figure 5.

Figure 5

EPHA2 S897 phosphorylation and FLI1 expression is decreased by dasatinib treatment and shows synergistic effect in combination with vemurafenib. (a) Protein expression levels of EPHA2/pEPHA2 and FLI1 analyzed by immunoblotting in presence of 1 μM dasatinib or DMSO as control treatment for 24 h. The lowest band for pEPHA2 in A375PR1 is unspecific. (b) Relative expression of FLI1 and EPHA2 mRNA after 24 h dasatinib treatment compared with DMSO control (Error bars represent S.D. of mean of three independent experiments). (c) Dose–response curves for 72 h dasatinib treatment of A375, A375VR4 and SKMEL24 cell lines showing cytoxic effect as % of DMSO control measured by MTS colorimetric assay. (Error bars represent S.D. of the mean of three independent experiments). (d) Single or combination treatment with vemurafenib+/-dasatinib for 72 h, showing cytoxic effect as % of DMSO control. Effect of low concentration of dasatinib combined (100 nM) with 10 μM vemurafenib in A375VR4 and SKMEL24 cell lines measured by MTS colorimetric assay. (Error bars represent S.D. of mean of three independent experiments)